ASCO 2012 LC Highlights: Dr. Joel Neal on the SELECT Trial of Tarceva (Erlotinib) As Adjuvant Therapy for EGFR Mutation-Positive Advanced NSCLC (audio)
- Author
- cancerGRACE - H. Jack West, MD
- Published
- Sun 16 Sep 2012
- Episode Link
- http://cancergrace.libsyn.com/asco-2012-lc-highlights-dr-joel-neal-on-the-select-trial-of-tarceva-erlotinib-as-adjuvant-therapy-for-egfr-mutation-positive-advanced-nsclc-audio
Dr. Joel Neal summarizes preliminary results of the SELECT trial of adjuvant Tarceva (erlotinib) for patients with resected EGFR mutation-positive early stage non-small cell lung cancer.
